DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Teen with sickle cell disease takes class trip to Europe with Loyola Medicine’s help
Anyah Randolph, a teenager with sickle cell disease (SCD), was recently able to join her school class on a trip to Europe – and even climb the Eiffel Tower in Paris after the elevator broke – thanks to the help of hydroxyurea and Loyola Medicine pediatricians.
Anyah had a difficult childhood, as she was always in the hospital, according to her mother, Lakisia Mobley. Her life began to change after she met Loyola Medicine pediatric hematologist Dr. Natalie Kamberos, who introduced her to a new medication: hydroxyurea, a drug that keeps the blood cells round and flexible.
+myBinderRelated Content
-
news & eventsPediatric sickle cell study stopped early due to positive resultsA national sickle cell disease study inv...
-
education & researchNovel use of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemiaHydroxyurea treatment is recommended for...
-
Community CenterPossible Cure for Sickle Cell Found in ParisHematologists, sickle cell patients, and...
-
education & researchDevelopment of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell AnemiaNational evidence-based guidelines recom...
-
news & eventsPreclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell ...ArQule, Inc. (Nasdaq: ARQL) today announ...
-
news & eventsFirst systemic evidence for safety of tPA in stroke patients with sickle cell diseaseIn the largest report on acute stroke in...
-
news & eventsCIRM and NHLBI Collaborating to Fund Cell and Gene Therapies for Sickle Cell DiseaseThe California Institute for Regenerativ...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.